View ValuationAlexandria Mineral Oils 将来の成長Future 基準チェック /16Alexandria Mineral Oilsの収益と利益は、それぞれ年間2.1%と4.9%減少すると予測されています。EPS は年間4.9%で 減少すると予想されています。自己資本利益率は 3 年後に23.2%になると予測されています。主要情報-4.9%収益成長率-4.85%EPS成長率Chemicals 収益成長1.1%収益成長率-2.1%将来の株主資本利益率23.24%アナリストカバレッジLow最終更新日20 May 2026今後の成長に関する最新情報Major Estimate Revision • Nov 29Consensus EPS estimates increase by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ج.م32.2b to ج.م32.6b. EPS estimate increased from ج.م1.27 to ج.م1.49 per share. Net income forecast to grow 83% next year vs 24% growth forecast for Chemicals industry in Egypt. Consensus price target up from ج.م8.83 to ج.م9.62. Share price was steady at ج.م10.25 over the past week.Major Estimate Revision • Sep 13Consensus revenue estimates increase by 11%, EPS downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from ج.م29.0b to ج.م32.1b. EPS estimate fell from ج.م1.52 to ج.م1.18. Net income forecast to grow 43% next year vs 7.1% decline forecast for Chemicals industry in Egypt. Consensus price target of ج.م9.12 unchanged from last update. Share price rose 6.2% to ج.م8.90 over the past week.Major Estimate Revision • Feb 19Consensus EPS estimates increase by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ج.م25.0b to ج.م26.9b. EPS estimate increased from ج.م1.22 to ج.م1.76 per share. Net income forecast to grow 24% next year vs 11% growth forecast for Chemicals industry in Egypt. Consensus price target up from ج.م7.02 to ج.م8.17. Share price rose 9.2% to ج.م8.64 over the past week.Major Estimate Revision • Nov 24Consensus EPS estimates fall by 58%The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from ج.م27.3b to ج.م25.8b. EPS estimate also fell from ج.م2.92 per share to ج.م1.24 per share. Net income forecast to grow 51% next year vs 37% growth forecast for Chemicals industry in Egypt. Consensus price target of ج.م6.33 unchanged from last update. Share price was steady at ج.م4.22 over the past week.Price Target Changed • Nov 16Price target increased to ج.م6.33Up from ج.م5.37, the current price target is provided by 1 analyst. New target price is 58% above last closing price of ج.م4.01. Stock is up 6.6% over the past year. The company is forecast to post earnings per share of ج.م2.92 for next year compared to ج.م0.83 last year.Major Estimate Revision • Sep 05Consensus revenue estimates increase by 11%The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from ج.م24.6b to ج.م27.3b. EPS estimate increased from ج.م1.14 to ج.م2.92 per share. Net income forecast to grow 202% next year vs 22% growth forecast for Chemicals industry in Egypt. Consensus price target of ج.م5.07 unchanged from last update. Share price was steady at ج.م4.04 over the past week.すべての更新を表示Recent updatesNew Risk • May 21New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.9% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.1% average weekly change).Board Change • May 21No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. No independent directors (12 non-independent directors). Chairman & MD Maged Kordy was the last director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Aug 21Alexandria Mineral Oils Company, Annual General Meeting, Sep 27, 2025Alexandria Mineral Oils Company, Annual General Meeting, Sep 27, 2025, at 10:00 Egypt Standard Time. Location: alexandarie EgyptNew Risk • Oct 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. High level of non-cash earnings (69% accrual ratio). Minor Risk Dividend is not well covered by cash flows (239% cash payout ratio).Upcoming Dividend • Oct 03Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 10 October 2024. Payment date: 12 February 2025. Payout ratio is a comfortable 60% but the company is paying out more than the cash it is generating. Trailing yield: 7.1%. Within top quartile of Egyptian dividend payers (5.9%). Higher than average of industry peers (6.2%).お知らせ • Aug 28Alexandria Mineral Oils Company, Annual General Meeting, Sep 21, 2024Alexandria Mineral Oils Company, Annual General Meeting, Sep 21, 2024, at 11:00 Egypt Standard Time. Location: alexandarie EgyptReported Earnings • Aug 20Full year 2024 earnings: Revenues exceed analyst expectationsFull year 2024 results: Revenue: ج.م33.8b (up 40% from FY 2023). Net income: ج.م1.70b (up 43% from FY 2023). Profit margin: 5.0% (up from 4.9% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.3%. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in Egypt.New Risk • Jun 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (9.6% average weekly change). Profit margins are more than 30% lower than last year (4.1% net profit margin).Reported Earnings • Jun 05Third quarter 2024 earnings released: EPS: ج.م0.35 (vs ج.م0.28 in 3Q 2023)Third quarter 2024 results: EPS: ج.م0.35 (up from ج.م0.28 in 3Q 2023). Revenue: ج.م8.47b (up 21% from 3Q 2023). Net income: ج.م460.4m (up 26% from 3Q 2023). Profit margin: 5.4% (up from 5.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ج.م8.20, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Egypt. Total returns to shareholders of 231% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م6.51 per share.Buy Or Sell Opportunity • May 19Now 26% overvaluedOver the last 90 days, the stock has fallen 18% to ج.م8.20. The fair value is estimated to be ج.م6.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.1% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.Buy Or Sell Opportunity • Apr 04Now 21% overvaluedOver the last 90 days, the stock has fallen 21% to ج.م7.95. The fair value is estimated to be ج.م6.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.1% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.Valuation Update With 7 Day Price Move • Mar 17Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ج.م7.84, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Egypt. Total returns to shareholders of 246% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م6.60 per share.Reported Earnings • Feb 17Second quarter 2024 earnings released: EPS: ج.م0.41 (vs ج.م0.44 in 2Q 2023)Second quarter 2024 results: EPS: ج.م0.41 (down from ج.م0.44 in 2Q 2023). Revenue: ج.م7.23b (up 49% from 2Q 2023). Net income: ج.م530.9m (down 7.0% from 2Q 2023). Profit margin: 7.3% (down from 12% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.Major Estimate Revision • Nov 29Consensus EPS estimates increase by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ج.م32.2b to ج.م32.6b. EPS estimate increased from ج.م1.27 to ج.م1.49 per share. Net income forecast to grow 83% next year vs 24% growth forecast for Chemicals industry in Egypt. Consensus price target up from ج.م8.83 to ج.م9.62. Share price was steady at ج.م10.25 over the past week.Reported Earnings • Nov 16First quarter 2024 earnings released: EPS: ج.م0.32 (vs ج.م0.24 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.32 (up from ج.م0.24 in 1Q 2023). Revenue: ج.م7.05b (up 20% from 1Q 2023). Net income: ج.م411.9m (up 32% from 1Q 2023). Profit margin: 5.8% (up from 5.3% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Oct 30Upcoming dividend of ج.م0.65 per share at 2.1% yieldEligible shareholders must have bought the stock before 06 November 2023. Payment date: 07 March 2024. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Egyptian dividend payers (7.2%). Lower than average of industry peers (3.9%).Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ج.م10.26, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the Chemicals industry in Egypt. Total returns to shareholders of 389% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م7.03 per share.Major Estimate Revision • Sep 13Consensus revenue estimates increase by 11%, EPS downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from ج.م29.0b to ج.م32.1b. EPS estimate fell from ج.م1.52 to ج.م1.18. Net income forecast to grow 43% next year vs 7.1% decline forecast for Chemicals industry in Egypt. Consensus price target of ج.م9.12 unchanged from last update. Share price rose 6.2% to ج.م8.90 over the past week.Reported Earnings • Sep 09Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ج.م0.74 (down from ج.م0.83 in FY 2022). Revenue: ج.م23.9b (up 30% from FY 2022). Net income: ج.م1.07b (flat on FY 2022). Profit margin: 4.5% (down from 5.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 43%. Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.New Risk • Sep 07New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ج.م8.36, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 5x in the Chemicals industry in Egypt. Total returns to shareholders of 381% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م6.48 per share.Major Estimate Revision • Feb 19Consensus EPS estimates increase by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ج.م25.0b to ج.م26.9b. EPS estimate increased from ج.م1.22 to ج.م1.76 per share. Net income forecast to grow 24% next year vs 11% growth forecast for Chemicals industry in Egypt. Consensus price target up from ج.م7.02 to ج.م8.17. Share price rose 9.2% to ج.م8.64 over the past week.Reported Earnings • Feb 14Second quarter 2023 earnings released: EPS: ج.م0.42 (vs ج.م0.14 in 2Q 2022)Second quarter 2023 results: EPS: ج.م0.42 (up from ج.م0.14 in 2Q 2022). Revenue: ج.م4.85b (up 41% from 2Q 2022). Net income: ج.م672.3m (up 199% from 2Q 2022). Profit margin: 14% (up from 6.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 1.7% decline forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م5.09, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 5x in the Chemicals industry in Egypt. Total returns to shareholders of 58% over the past three years.Major Estimate Revision • Nov 24Consensus EPS estimates fall by 58%The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from ج.م27.3b to ج.م25.8b. EPS estimate also fell from ج.م2.92 per share to ج.م1.24 per share. Net income forecast to grow 51% next year vs 37% growth forecast for Chemicals industry in Egypt. Consensus price target of ج.م6.33 unchanged from last update. Share price was steady at ج.م4.22 over the past week.Price Target Changed • Nov 16Price target increased to ج.م6.33Up from ج.م5.37, the current price target is provided by 1 analyst. New target price is 58% above last closing price of ج.م4.01. Stock is up 6.6% over the past year. The company is forecast to post earnings per share of ج.م2.92 for next year compared to ج.م0.83 last year.Board Change • Nov 16No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 11 non-independent directors. MD & Chairman of the Board Amr Morsi was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.Upcoming Dividend • Oct 11Upcoming dividend of ج.م0.55 per shareEligible shareholders must have bought the stock before 18 October 2022. Payment date: 22 February 2023. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 5.9%. Lower than top quartile of Egyptian dividend payers (10%). Lower than average of industry peers (8.8%).Major Estimate Revision • Sep 05Consensus revenue estimates increase by 11%The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from ج.م24.6b to ج.م27.3b. EPS estimate increased from ج.م1.14 to ج.م2.92 per share. Net income forecast to grow 202% next year vs 22% growth forecast for Chemicals industry in Egypt. Consensus price target of ج.م5.07 unchanged from last update. Share price was steady at ج.م4.04 over the past week.Buying Opportunity • Jun 14Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 4.5%. The fair value is estimated to be ج.م4.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 1.3% per annum. Earnings is also forecast to decline by 0.3% per annum over the same time period.Major Estimate Revision • May 30Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from ج.م14.2b to ج.م18.7b. EPS estimate unchanged from ج.م0.80 at last update. Chemicals industry in Egypt expected to see average net income growth of 35% next year. Consensus price target of ج.م4.73 unchanged from last update. Share price fell 4.6% to ج.م3.54 over the past week.Buying Opportunity • May 25Now 22% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ج.م4.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 1.9% per annum. Earnings is also forecast to decline by 1.8% per annum over the same time period.Board Change • Apr 27No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 11 non-independent directors. Non-Executive Director Mohamed Fayad was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.Buying Opportunity • Apr 14Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be ج.م4.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 0.7% per annum. Earnings is also forecast to decline by 0.1% per annum over the same time period.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م4.28, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 6x in the Chemicals industry in Egypt. Total loss to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م4.38 per share.Price Target Changed • Jan 17Price target decreased to ج.م4.78Down from ج.م5.37, the current price target is an average from 4 analysts. New target price is 17% above last closing price of ج.م4.10. Stock is up 26% over the past year. The company is forecast to post earnings per share of ج.م0.47 for next year compared to ج.م0.33 last year.Price Target Changed • Nov 16Price target increased to ج.م5.37Up from ج.م4.78, the current price target is an average from 5 analysts. New target price is 46% above last closing price of ج.م3.67. Stock is up 42% over the past year. The company is forecast to post earnings per share of ج.م0.57 for next year compared to ج.م0.33 last year.Upcoming Dividend • Oct 12Upcoming dividend of ج.م0.15 per shareEligible shareholders must have bought the stock before 19 October 2021. Payment date: 21 October 2021. Trailing yield: 3.8%. Lower than top quartile of Egyptian dividend payers (7.4%). Lower than average of industry peers (5.1%).Reported Earnings • Feb 08Second quarter 2021 earnings released: ج.م0.01 loss per share (vs ج.م0.049 profit in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: ج.م2.25b (down 1.9% from 2Q 2020). Net loss: ج.م13.4m (down 121% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 95% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.Analyst Estimate Surprise Post Earnings • Feb 08Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates. Over the next year, revenue is forecast to grow 27%, compared to a 39% growth forecast for the Chemicals industry in Egypt.Is New 90 Day High Low • Dec 08New 90-day high: ج.م3.04The company is up 18% from its price of ج.م2.58 on 09 September 2020. The Egyptian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م0.82 per share.お知らせ • Nov 24+ 1 more updateAlexandria Mineral Oils Company Names Mohamed Mostafa Sayed Ahmed Sheta as Managing DirectorEl-Molla appointed Mohamed Mostafa Sayed Ahmed Sheta as the Chairman and Managing Director of Alexandria Mineral Oils Co (AMOC).Is New 90 Day High Low • Nov 01New 90-day low: ج.م2.33The company is down 3.0% from its price of ج.م2.41 on 29 July 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م0.85 per share.業績と収益の成長予測CASE:AMOC - アナリストの将来予測と過去の財務データ ( )EGP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202840,3811,4511,0261,28126/30/202741,5801,8261,7832,02526/30/202644,6262,3811,0011,679212/31/202540,1121,5031,2951,515N/A9/30/202539,1031,35443349N/A6/30/202537,6231,4886891,060N/A12/31/202437,739997-971-616N/A9/30/202435,6081,5649591,253N/A6/30/202433,7681,260192435N/A3/31/202429,2201,3981,3141,505N/A12/31/202327,7741,1152,2742,437N/A9/30/202325,3061,2092,3782,512N/A6/30/202324,2081,1912,2172,329N/A3/31/202323,9111,3261,7051,751N/A12/31/202222,0511,5929641,034N/A9/30/202220,7261,243765830N/A6/30/202218,4421,067480540N/A3/31/202215,3471,006256312N/A12/31/202113,028838554585N/A9/30/202111,847642220253N/A6/30/202110,183432552583N/A3/31/20218,285-233-531-486N/A12/31/20207,817-627-1,141-1,111N/A9/30/20207,859-551-2,116-2,074N/A6/30/20208,984-488-2,066-2,024N/A3/31/202011,516-58-408-401N/A12/31/201912,497245313335N/A9/30/201913,685201N/A1,927N/A6/30/201914,858400N/A2,813N/A3/31/201915,169684N/A2,446N/A12/31/201815,562943N/A2,215N/A9/30/201814,6101,235N/A1,518N/A6/30/201814,0331,334N/A-19N/A3/31/201813,0351,162N/A111N/A12/31/201712,6111,161N/A196N/A9/30/201711,8931,279N/A564N/A6/30/20179,590982N/A1,092N/A3/31/20177,749905N/A747N/A12/31/20165,403720N/A504N/A9/30/20164,303359N/A457N/A6/30/20164,376389N/A425N/A3/31/20164,827334N/A445N/A12/31/20155,003273N/A339N/A9/30/20155,634286N/A263N/A6/30/20156,429303N/A451N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AMOCの収益は今後 3 年間で減少すると予測されています (年間-4.9% )。収益対市場: AMOCの収益は今後 3 年間で減少すると予測されています (年間-4.9% )。高成長収益: AMOCの収益は今後 3 年間で減少すると予測されています。収益対市場: AMOCの収益は今後 3 年間で減少すると予想されています (年間-2.1% )。高い収益成長: AMOCの収益は今後 3 年間で減少すると予測されています (年間-2.1% )。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AMOCの 自己資本利益率 は、3年後には高くなると予測されています ( 23.2 %)成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/07 08:38終値2026/06/07 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Alexandria Mineral Oils Company 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Nour SherifArqaam Capital Research Offshore S.A.L.Passant MohamedArqaam Capital Research Offshore S.A.L.Dareen El ArousyBeltone Financial5 その他のアナリストを表示
Major Estimate Revision • Nov 29Consensus EPS estimates increase by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ج.م32.2b to ج.م32.6b. EPS estimate increased from ج.م1.27 to ج.م1.49 per share. Net income forecast to grow 83% next year vs 24% growth forecast for Chemicals industry in Egypt. Consensus price target up from ج.م8.83 to ج.م9.62. Share price was steady at ج.م10.25 over the past week.
Major Estimate Revision • Sep 13Consensus revenue estimates increase by 11%, EPS downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from ج.م29.0b to ج.م32.1b. EPS estimate fell from ج.م1.52 to ج.م1.18. Net income forecast to grow 43% next year vs 7.1% decline forecast for Chemicals industry in Egypt. Consensus price target of ج.م9.12 unchanged from last update. Share price rose 6.2% to ج.م8.90 over the past week.
Major Estimate Revision • Feb 19Consensus EPS estimates increase by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ج.م25.0b to ج.م26.9b. EPS estimate increased from ج.م1.22 to ج.م1.76 per share. Net income forecast to grow 24% next year vs 11% growth forecast for Chemicals industry in Egypt. Consensus price target up from ج.م7.02 to ج.م8.17. Share price rose 9.2% to ج.م8.64 over the past week.
Major Estimate Revision • Nov 24Consensus EPS estimates fall by 58%The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from ج.م27.3b to ج.م25.8b. EPS estimate also fell from ج.م2.92 per share to ج.م1.24 per share. Net income forecast to grow 51% next year vs 37% growth forecast for Chemicals industry in Egypt. Consensus price target of ج.م6.33 unchanged from last update. Share price was steady at ج.م4.22 over the past week.
Price Target Changed • Nov 16Price target increased to ج.م6.33Up from ج.م5.37, the current price target is provided by 1 analyst. New target price is 58% above last closing price of ج.م4.01. Stock is up 6.6% over the past year. The company is forecast to post earnings per share of ج.م2.92 for next year compared to ج.م0.83 last year.
Major Estimate Revision • Sep 05Consensus revenue estimates increase by 11%The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from ج.م24.6b to ج.م27.3b. EPS estimate increased from ج.م1.14 to ج.م2.92 per share. Net income forecast to grow 202% next year vs 22% growth forecast for Chemicals industry in Egypt. Consensus price target of ج.م5.07 unchanged from last update. Share price was steady at ج.م4.04 over the past week.
New Risk • May 21New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.9% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.1% average weekly change).
Board Change • May 21No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. No independent directors (12 non-independent directors). Chairman & MD Maged Kordy was the last director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Aug 21Alexandria Mineral Oils Company, Annual General Meeting, Sep 27, 2025Alexandria Mineral Oils Company, Annual General Meeting, Sep 27, 2025, at 10:00 Egypt Standard Time. Location: alexandarie Egypt
New Risk • Oct 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. High level of non-cash earnings (69% accrual ratio). Minor Risk Dividend is not well covered by cash flows (239% cash payout ratio).
Upcoming Dividend • Oct 03Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 10 October 2024. Payment date: 12 February 2025. Payout ratio is a comfortable 60% but the company is paying out more than the cash it is generating. Trailing yield: 7.1%. Within top quartile of Egyptian dividend payers (5.9%). Higher than average of industry peers (6.2%).
お知らせ • Aug 28Alexandria Mineral Oils Company, Annual General Meeting, Sep 21, 2024Alexandria Mineral Oils Company, Annual General Meeting, Sep 21, 2024, at 11:00 Egypt Standard Time. Location: alexandarie Egypt
Reported Earnings • Aug 20Full year 2024 earnings: Revenues exceed analyst expectationsFull year 2024 results: Revenue: ج.م33.8b (up 40% from FY 2023). Net income: ج.م1.70b (up 43% from FY 2023). Profit margin: 5.0% (up from 4.9% in FY 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.3%. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in Egypt.
New Risk • Jun 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (9.6% average weekly change). Profit margins are more than 30% lower than last year (4.1% net profit margin).
Reported Earnings • Jun 05Third quarter 2024 earnings released: EPS: ج.م0.35 (vs ج.م0.28 in 3Q 2023)Third quarter 2024 results: EPS: ج.م0.35 (up from ج.م0.28 in 3Q 2023). Revenue: ج.م8.47b (up 21% from 3Q 2023). Net income: ج.م460.4m (up 26% from 3Q 2023). Profit margin: 5.4% (up from 5.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ج.م8.20, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Egypt. Total returns to shareholders of 231% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م6.51 per share.
Buy Or Sell Opportunity • May 19Now 26% overvaluedOver the last 90 days, the stock has fallen 18% to ج.م8.20. The fair value is estimated to be ج.م6.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.1% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
Buy Or Sell Opportunity • Apr 04Now 21% overvaluedOver the last 90 days, the stock has fallen 21% to ج.م7.95. The fair value is estimated to be ج.م6.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 40% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.1% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ج.م7.84, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Egypt. Total returns to shareholders of 246% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م6.60 per share.
Reported Earnings • Feb 17Second quarter 2024 earnings released: EPS: ج.م0.41 (vs ج.م0.44 in 2Q 2023)Second quarter 2024 results: EPS: ج.م0.41 (down from ج.م0.44 in 2Q 2023). Revenue: ج.م7.23b (up 49% from 2Q 2023). Net income: ج.م530.9m (down 7.0% from 2Q 2023). Profit margin: 7.3% (down from 12% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
Major Estimate Revision • Nov 29Consensus EPS estimates increase by 17%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from ج.م32.2b to ج.م32.6b. EPS estimate increased from ج.م1.27 to ج.م1.49 per share. Net income forecast to grow 83% next year vs 24% growth forecast for Chemicals industry in Egypt. Consensus price target up from ج.م8.83 to ج.م9.62. Share price was steady at ج.م10.25 over the past week.
Reported Earnings • Nov 16First quarter 2024 earnings released: EPS: ج.م0.32 (vs ج.م0.24 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.32 (up from ج.م0.24 in 1Q 2023). Revenue: ج.م7.05b (up 20% from 1Q 2023). Net income: ج.م411.9m (up 32% from 1Q 2023). Profit margin: 5.8% (up from 5.3% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Oct 30Upcoming dividend of ج.م0.65 per share at 2.1% yieldEligible shareholders must have bought the stock before 06 November 2023. Payment date: 07 March 2024. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Egyptian dividend payers (7.2%). Lower than average of industry peers (3.9%).
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ج.م10.26, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the Chemicals industry in Egypt. Total returns to shareholders of 389% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م7.03 per share.
Major Estimate Revision • Sep 13Consensus revenue estimates increase by 11%, EPS downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from ج.م29.0b to ج.م32.1b. EPS estimate fell from ج.م1.52 to ج.م1.18. Net income forecast to grow 43% next year vs 7.1% decline forecast for Chemicals industry in Egypt. Consensus price target of ج.م9.12 unchanged from last update. Share price rose 6.2% to ج.م8.90 over the past week.
Reported Earnings • Sep 09Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ج.م0.74 (down from ج.م0.83 in FY 2022). Revenue: ج.م23.9b (up 30% from FY 2022). Net income: ج.م1.07b (flat on FY 2022). Profit margin: 4.5% (down from 5.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.3%. Earnings per share (EPS) also missed analyst estimates by 43%. Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.
New Risk • Sep 07New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ج.م8.36, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 5x in the Chemicals industry in Egypt. Total returns to shareholders of 381% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م6.48 per share.
Major Estimate Revision • Feb 19Consensus EPS estimates increase by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ج.م25.0b to ج.م26.9b. EPS estimate increased from ج.م1.22 to ج.م1.76 per share. Net income forecast to grow 24% next year vs 11% growth forecast for Chemicals industry in Egypt. Consensus price target up from ج.م7.02 to ج.م8.17. Share price rose 9.2% to ج.م8.64 over the past week.
Reported Earnings • Feb 14Second quarter 2023 earnings released: EPS: ج.م0.42 (vs ج.م0.14 in 2Q 2022)Second quarter 2023 results: EPS: ج.م0.42 (up from ج.م0.14 in 2Q 2022). Revenue: ج.م4.85b (up 41% from 2Q 2022). Net income: ج.م672.3m (up 199% from 2Q 2022). Profit margin: 14% (up from 6.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 1.7% decline forecast for the Chemicals industry in Egypt. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م5.09, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 5x in the Chemicals industry in Egypt. Total returns to shareholders of 58% over the past three years.
Major Estimate Revision • Nov 24Consensus EPS estimates fall by 58%The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from ج.م27.3b to ج.م25.8b. EPS estimate also fell from ج.م2.92 per share to ج.م1.24 per share. Net income forecast to grow 51% next year vs 37% growth forecast for Chemicals industry in Egypt. Consensus price target of ج.م6.33 unchanged from last update. Share price was steady at ج.م4.22 over the past week.
Price Target Changed • Nov 16Price target increased to ج.م6.33Up from ج.م5.37, the current price target is provided by 1 analyst. New target price is 58% above last closing price of ج.م4.01. Stock is up 6.6% over the past year. The company is forecast to post earnings per share of ج.م2.92 for next year compared to ج.م0.83 last year.
Board Change • Nov 16No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 11 non-independent directors. MD & Chairman of the Board Amr Morsi was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
Upcoming Dividend • Oct 11Upcoming dividend of ج.م0.55 per shareEligible shareholders must have bought the stock before 18 October 2022. Payment date: 22 February 2023. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 5.9%. Lower than top quartile of Egyptian dividend payers (10%). Lower than average of industry peers (8.8%).
Major Estimate Revision • Sep 05Consensus revenue estimates increase by 11%The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from ج.م24.6b to ج.م27.3b. EPS estimate increased from ج.م1.14 to ج.م2.92 per share. Net income forecast to grow 202% next year vs 22% growth forecast for Chemicals industry in Egypt. Consensus price target of ج.م5.07 unchanged from last update. Share price was steady at ج.م4.04 over the past week.
Buying Opportunity • Jun 14Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 4.5%. The fair value is estimated to be ج.م4.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 1.3% per annum. Earnings is also forecast to decline by 0.3% per annum over the same time period.
Major Estimate Revision • May 30Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from ج.م14.2b to ج.م18.7b. EPS estimate unchanged from ج.م0.80 at last update. Chemicals industry in Egypt expected to see average net income growth of 35% next year. Consensus price target of ج.م4.73 unchanged from last update. Share price fell 4.6% to ج.م3.54 over the past week.
Buying Opportunity • May 25Now 22% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ج.م4.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 1.9% per annum. Earnings is also forecast to decline by 1.8% per annum over the same time period.
Board Change • Apr 27No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 11 non-independent directors. Non-Executive Director Mohamed Fayad was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
Buying Opportunity • Apr 14Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be ج.م4.36, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 15% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to decline by 0.7% per annum. Earnings is also forecast to decline by 0.1% per annum over the same time period.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م4.28, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 6x in the Chemicals industry in Egypt. Total loss to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م4.38 per share.
Price Target Changed • Jan 17Price target decreased to ج.م4.78Down from ج.م5.37, the current price target is an average from 4 analysts. New target price is 17% above last closing price of ج.م4.10. Stock is up 26% over the past year. The company is forecast to post earnings per share of ج.م0.47 for next year compared to ج.م0.33 last year.
Price Target Changed • Nov 16Price target increased to ج.م5.37Up from ج.م4.78, the current price target is an average from 5 analysts. New target price is 46% above last closing price of ج.م3.67. Stock is up 42% over the past year. The company is forecast to post earnings per share of ج.م0.57 for next year compared to ج.م0.33 last year.
Upcoming Dividend • Oct 12Upcoming dividend of ج.م0.15 per shareEligible shareholders must have bought the stock before 19 October 2021. Payment date: 21 October 2021. Trailing yield: 3.8%. Lower than top quartile of Egyptian dividend payers (7.4%). Lower than average of industry peers (5.1%).
Reported Earnings • Feb 08Second quarter 2021 earnings released: ج.م0.01 loss per share (vs ج.م0.049 profit in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: ج.م2.25b (down 1.9% from 2Q 2020). Net loss: ج.م13.4m (down 121% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 95% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
Analyst Estimate Surprise Post Earnings • Feb 08Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates. Over the next year, revenue is forecast to grow 27%, compared to a 39% growth forecast for the Chemicals industry in Egypt.
Is New 90 Day High Low • Dec 08New 90-day high: ج.م3.04The company is up 18% from its price of ج.م2.58 on 09 September 2020. The Egyptian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م0.82 per share.
お知らせ • Nov 24+ 1 more updateAlexandria Mineral Oils Company Names Mohamed Mostafa Sayed Ahmed Sheta as Managing DirectorEl-Molla appointed Mohamed Mostafa Sayed Ahmed Sheta as the Chairman and Managing Director of Alexandria Mineral Oils Co (AMOC).
Is New 90 Day High Low • Nov 01New 90-day low: ج.م2.33The company is down 3.0% from its price of ج.م2.41 on 29 July 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م0.85 per share.